Ok_老虎社区_美港股上老虎

jojoc
2021-12-30

Biogen Shares Leap Following Korean Report of Deal Talks

Biogen Inc.shares jumped by the most since the company’s Alzheimer’s disease treatment was approved

Biogen Shares Leap Following Korean Report of Deal Talks

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":692910148,"tweetId":"692910148","gmtCreate":1640825526083,"gmtModify":1640825526301,"author":{"id":4099442649801160,"idStr":"4099442649801160","authorId":4099442649801160,"authorIdStr":"4099442649801160","name":"jojoc","avatar":"https://static.tigerbbs.com/ccc8519a0bdc4ba6b43a9aa8afa0e63c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ok</p></body></html>","htmlText":"<html><head></head><body><p>Ok</p></body></html>","text":"Ok","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/692910148","repostId":1107504568,"repostType":4,"repost":{"id":"1107504568","pubTimestamp":1640824341,"share":"https://www.laohu8.com/m/news/1107504568?lang=&edition=full","pubTime":"2021-12-30 08:32","market":"us","language":"en","title":"Biogen Shares Leap Following Korean Report of Deal Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=1107504568","media":"Bloomberg","summary":"Biogen Inc.shares jumped by the most since the company’s Alzheimer’s disease treatment was approved ","content":"<html><head></head><body><p>Biogen Inc.shares jumped by the most since the company’s Alzheimer’s disease treatment was approved in the U.S. this spring, after a Korean media report that it was in talks to sell itself to Samsung Group.</p><p>The Korea Economic Daily reported, citing unnamed sources, that the Cambridge, Massachusetts-based biotechnology company had approached the Seoul conglomerate about a takeover.</p><p>A representative for Biogen said that the company doesn’t comment on market rumors and speculation. A spokesperson for Samsung Biologics Co., a biotech unit of the Samsung Group, said the story was a rumor and declined to comment further.</p><p>Biogen’s stock gained as much as 13%, the biggest intraday advance since June 7, before ending the day up 9.5% at $258.31.</p><p>A deal for Biogen, with a market value of $38 billion after Wednesday’s jump, would top the $34 billion Medline Industries Inc. transaction, now the second-biggest acquisition of 2021, according to data compiled by Bloomberg.</p><p>With a typical premium, a Biogen acquisition would likely approach or surpass Discovery Inc.’s $43 billion deal for Warner Media LLC that was announced in May, the data show.</p><p>Biogen gained approval for its Alzheimer’s treatment Aduhelm in June over the objections of experts who said there wasn’t enough clear evidence that it worked. Since then, the drug has struggled to gain momentum as patients and payers balked at the scientific debate and the treatment’s $56,000-a-year cost. Biogen has since cut the drug’s price in half.</p><p>There are existing ties between the companies. Samsung Bioepis is a joint venture between Samsung Biologics and Biogen focused on making low-cost biosimiliars. Its version of macular degeneration treatment Lucentis was approved in the U.S. in September.</p><p></p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Shares Leap Following Korean Report of Deal Talks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Shares Leap Following Korean Report of Deal Talks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 08:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-29/biogen-shares-leap-following-korean-report-of-deal-talks><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc.shares jumped by the most since the company’s Alzheimer’s disease treatment was approved in the U.S. this spring, after a Korean media report that it was in talks to sell itself to Samsung ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-29/biogen-shares-leap-following-korean-report-of-deal-talks\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-29/biogen-shares-leap-following-korean-report-of-deal-talks","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107504568","content_text":"Biogen Inc.shares jumped by the most since the company’s Alzheimer’s disease treatment was approved in the U.S. this spring, after a Korean media report that it was in talks to sell itself to Samsung Group.The Korea Economic Daily reported, citing unnamed sources, that the Cambridge, Massachusetts-based biotechnology company had approached the Seoul conglomerate about a takeover.A representative for Biogen said that the company doesn’t comment on market rumors and speculation. A spokesperson for Samsung Biologics Co., a biotech unit of the Samsung Group, said the story was a rumor and declined to comment further.Biogen’s stock gained as much as 13%, the biggest intraday advance since June 7, before ending the day up 9.5% at $258.31.A deal for Biogen, with a market value of $38 billion after Wednesday’s jump, would top the $34 billion Medline Industries Inc. transaction, now the second-biggest acquisition of 2021, according to data compiled by Bloomberg.With a typical premium, a Biogen acquisition would likely approach or surpass Discovery Inc.’s $43 billion deal for Warner Media LLC that was announced in May, the data show.Biogen gained approval for its Alzheimer’s treatment Aduhelm in June over the objections of experts who said there wasn’t enough clear evidence that it worked. Since then, the drug has struggled to gain momentum as patients and payers balked at the scientific debate and the treatment’s $56,000-a-year cost. Biogen has since cut the drug’s price in half.There are existing ties between the companies. Samsung Bioepis is a joint venture between Samsung Biologics and Biogen focused on making low-cost biosimiliars. Its version of macular degeneration treatment Lucentis was approved in the U.S. in September.","news_type":1},"isVote":1,"tweetType":1,"viewCount":736,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}